Compare BridgeBio Pharma Inc (BBIO) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs YieldMax NVDA Option Income Strategy ETF — how do they compare? BridgeBio Pharma Inc trades at $84.9 (market cap $16.46B), while YieldMax NVDA Option Income Strategy ETF trades at $12.83. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | NVDY | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $90.17 | $17.96 |
52-Week Low | $44.81 | $12.03 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
NVDY, the YieldMax NVDA Option Income Strategy ETF, trades at $12.43, down 2.51% today, reflecting bearish technical signals with moving averages indicating selling pressure. The fund generates weekly dividends but lacks traditional valuation metrics like P/E or P/S, as it is structured to monetize NVIDIA's volatility through options strategies. Recent news highlights its focus on income generation at the potential cost of capping NVIDIA's upside returns.
The outlook for NVDY hinges on sustained options premium income amid NVIDIA's stock volatility, offering high distribution yields but limiting capital appreciation. Key risks include underperformance versus holding NVIDIA directly, fee drag, and dependency on market conditions for options profitability. Investors seeking income may find value, but growth-oriented investors face significant opportunity cost.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
